32: Weekly Dose Podcast: FDA Breakthrough in Acromegaly, Alcohol–Dementia Risk Clarified, Tirzepatide in Youth T2D, Precision Mood Gains, and Major Contraception Practice Insights

<div>Primary Viewpoints from <em>Patient Care Online</em> features informative conversations with health care experts, opinion leaders, and practicing physicians, about what impacts primary care medicine today.</div>

Medicine

Health & Fitness

Primary Viewpoints from Patient Care Online features informative conversations with health care experts, opinion leaders, and practicing physicians, about what impacts primary care medicine today.

Primary Viewpoints from <em>Patient Care Online</em> features informative conversations with health care experts, opinion leaders, and practicing physicians, about what impacts primary care medicine today.

Share 32: Weekly Dose Podcast: FDA Breakthrough in Acromegaly, Alcohol–Dementia Risk Clarified, Tirzepatide in Youth T2D, Precision Mood Gains, and Major Contraception Practice Insights

Sign up to save your podcasts

32: Weekly Dose Podcast: FDA Breakthrough in Acromegaly, Alcohol–Dementia Risk Clarified, Tirzepatide in Youth T2D, Precision Mood Gains, and Major Contraception Practice Insights

32: Weekly Dose Podcast: FDA Breakthrough in Acromegaly, Alcohol–Dementia Risk Clarified, Tirzepatide in Youth T2D, Precision Mood Gains, and Major Contraception Practice Insights